Clinical Features of Glutamic Acid Decarboxylase‐65 Neurological Autoimmunity: A Case Series From China
CNS Neuroscience & Therapeutics · 2025-02 · 31 (2)
DOI: 10.1111/cns.70237 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 20.02.2025. Verfasst von Zhandong Qiu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders, Beijing, China. Hauptthemen laut MEDLINE: Glutamate Decarboxylase, Autoantibodies, Autoimmune Diseases of the Nervous System, Autoimmunity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: parallel project 5 of Beijing Research Ward Excellence Program,BRWEP.
Abstract (Originalsprache)
Objective
To explore the clinical phenotypes, characteristics, immunotherapy response, and outcomes of glutamic acid decarboxylase‐65 (GAD65) neurological autoimmunity.
Methods
We performed a retrospective review of patients diagnosed with GAD65 neurological autoimmunity in the Department of Neurology at Xuanwu Hospital over the past 6 years (2017–2023). The clinical and laboratory data, imaging, therapeutic response, and long‐term prognosis of those patients were collected and analyzed.
Results
Among the 37 patients displaying significant neurological impairment, there were 14 males (37.8%) and 23 females (62.2%), with a median age of onset of 41.5 (25–59) years and a median interval of 9 (1.5–36) months from onset to a definitive diagnosis. Clinical phenotypes included epilepsy (15, 40.5%), limbic encephalitis (7, 18.9%), brainstem dysfunction (2, 5.4%), parkinsonism (2, 5.4%), peripheral neuropathy (3, 8.1%), cerebellar ataxia (1, 2.7%), and overlap syndromes (7, 18.9%). Out of 36 patients who received immunotherapy, the median time from onset to initiation of immunotherapy was 8.5 (1.5–37.5) months. Four cases were lost to follow‐up, leaving a median follow‐up period of 20.5 (16–37.25) months among the remaining 32 patients. Most patients (26, 81.3%) responded positively to immunotherapy, with some showing mild improvement or no response. Some patients showed inadequate responses to treatments such as mycophenolate mofetil (MMF), but significant improvement is observed after switching to rituximab (RTX). The relationship between the timing of initiating immunotherapy and prognosis by Spearman's rank correlation only showed weak correlation.
Conclusion
The clinical spectrum of GAD65 neurological autoimmunity appeared highly diverse. Immunotherapy can benefit the majority of patients, and early treatment appeared to be associated with good prognosis. RTX may be more effective than MMF; however, this requires more rigorous prospective studies to explore.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders, Beijing, China.
ORCID-Profile: Zhandong Qiu
Förderung
- parallel project 5 of Beijing Research Ward Excellence Program,BRWEP
Zitieren
APA
Qiu, Z., Xu, F., Zhang, M., Yang, X., Han, Y., Li, D., Liu, L., Chen, J., Gao, L., Xue, Q., Hou, Y., Sun, Y., Di, L., Fan, C., Liang, J., Han, Y., Dong, H., Hao, J., & Liu, Z. (2025). Clinical Features of Glutamic Acid Decarboxylase‐65 Neurological Autoimmunity: A Case Series From China. CNS Neuroscience & Therapeutics, 31(2). https://doi.org/10.1111/cns.70237
Vancouver
Qiu Z, Xu F, Zhang M, Yang X, Han Y, Li D, et al. Clinical Features of Glutamic Acid Decarboxylase‐65 Neurological Autoimmunity: A Case Series From China. CNS Neuroscience & Therapeutics. 2025;31(2). doi:10.1111/cns.70237
BibTeX
@article{Qiu2025,
author = {Qiu, Zhandong and Xu, Fang and Zhang, Mengyao and Yang, Xixi and Han, Yan and Li, Dawei and Liu, Liang and Chen, Jia and Gao, Lehong and Xue, Qing and Hou, Yue and Sun, Ying and Di, Li and Fan, Chunqiu and Liang, Junhua and Han, Yue and Dong, Huiqing and Hao, Junwei and Liu, Zheng},
title = {Clinical Features of Glutamic Acid Decarboxylase‐65 Neurological Autoimmunity: A Case Series From China},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
volume = {31},
number = {2},
doi = {10.1111/cns.70237}
}
EUVIMED